Superworth

Bristol-Myers Squibb BMY

Drug Manufacturers - General, Healthcare
$62.98
−0.06%
Market cap
$128.7B
PE
14.0×
10y median 19.9×
Forward PE
9.8×
10y median 10.2×
Price to sales
2.6×
EV/EBIT
n/m
a quarter missing
Revenue, 12 months
$50B
+4% on a year ago
Net margin
18.5%
Free cash flow yield
n/m
Q3 FY26 missing

Bristol-Myers Squibb trades at 14.0× trailing earnings, cheaper than 88% of the last ten years. Revenue was $50B over the last twelve months, up 4% on a year earlier with a 18% net margin.

Charts

Financials

Income statement for BMY, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$11.5B+1%$11.9B+5%$12.2B+9%$11.9B+8%$12.3B+8%$11.2B−6%$12.3B+1%$12.2B+3%$12.5B+1%$11.5B+3%$13B+6%$13.1B+7%
Cost of revenue$2.7B+6%$2.9B+14%$3.3B+14%$3B+18%$4.8B+75%$3B+3%$3.4B+3%$3.4B+16%$4.1B−15%$3.4B+13%$3.7B+11%$4.1B+21%
Gross profit$8.7B−1%$8.9B+2%$8.9B+7%$8.9B+6%$7.5B−14%$8.2B−9%$8.9B−0%$8.8B−2%$8.4B+12%$8.1B−1%$9.2B+4%n/a
R&D$2.5B−1%$2.7B+16%$2.9B+28%$2.4B+6%$3.2B+29%$2.3B−16%$2.6B−11%$2.5B+7%$2.6B−19%$2.6B+17%$3B+15%$2.4B−6%
SG&A$2.1B−9%$2.4B+34%$1.9B−0%$2B−1%$2.1B+3%$1.6B−33%$1.7B−11%$1.8B−10%$2.2B+2%$1.6B+2%$1.8B+7%$1.7B−5%
$1.3B−21%−$11.4B$1.6B−11%$1.9B+2%$480M−63%$3.3B$2.3B+45%$3B+57%$1.4B+196%$3.3B−1%$4B+78%n/a
Interest expense$316M+8%$425M+48%$521M+85%$505M+80%$496M+57%$494M+16%$485M−7%$480M−5%$432M−13%$411M−17%$407M−16%n/a
Pre-tax income$1.7B−10%−$11.5B$1.3B−31%$1.7B−22%$175M−90%$3B$1.8B+38%$3.1B+86%$1.5B+740%$3.2B+9%$4.1B+131%$2.5B−19%
−$88M−47%$392M−22%−$398M+83%$461M+127%$99M$509M+30%$460M$919M+99%$384M+288%$561M+10%$770M+67%n/a
Net income$1.8B−13%−$11.9B$1.7B−19%$1.2B−37%$72M−96%$2.5B$1.3B−22%$2.2B+82%$1.1B+1410%$2.7B+9%$3.3B+153%$2.2B−2%
$0.87−8%−$5.89$0.83−16%$0.60−36%$0.04−95%$1.20$0.64−23%$1.08+80%$0.53+1225%$1.31+9%$1.62+153%$1.05−3%
2B−4%2B−4%2B−4%2B−2%2B+0%2B+1%2B+0%2B+0%2B+0%2B+0%2B+1%2.1B+1%

Gross profit: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.

Operating income: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.

Net income: 4 periods, Q4 FY21 to Q4 FY25: printed in the fourth-quarter results release.

EPS, diluted: 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q4 FY11: quarter's net income to common over its shares, to the cent.

Diluted shares: 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. 7 periods, Q4 FY10 to Q4 FY18: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY15 to Q4 FY20: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.

Estimates

Next earnings report: .

QuarterRevenueRangeEPSRangeAnalysts
Q4 FY26$12.7B$12.4B to $12.8B$1.52$1.44 to $1.6515
Q1 FY27$11.3B$10.9B to $11.7B$1.51$1.37 to $1.647
Q2 FY27$12.4B$12B to $12.7B$1.72$1.65 to $1.772
Q3 FY27$12.4B$12.1B to $12.7B$1.68$1.61 to $1.732
Q4 FY27$12.4B$12B to $12.7B$1.59$1.53 to $1.645
Q1 FY28$10.5B$10.1B to $10.7B$1.33$1.28 to $1.376
Q2 FY28$10.8B$10.5B to $11.1B$1.46$1.41 to $1.515
Q3 FY28$11B$10.6B to $11.2B$1.48$1.42 to $1.524

Peers

Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
BMYBristol-Myers Squibb$128.7B14.0×19.9×9.8×2.6×+4%18.5%
PFEPfizer$176B40.6×15.8×11.2×2.8×−0%6.8%
GILDGilead Sciences$212.5Bn/m18.8×19.8×6.9×+7%−12.5%
AMGNAmgen$252.3B29.0×21.2×19.8×6.6×+9%23.0%
MRKMerck$359.5B150×25.0×17.2×5.3×+5%3.6%
BIIBBiogen$37B44.3×16.2×19.0×3.7×+0%8.3%
ABBVAbbVie$511.6B49.8×27.9×18.3×7.7×+11%15.7%
JNJJohnson & Johnson$650.2B40.9×24.3×23.9×6.5×+8%n/m
JAZZJazz Pharmaceuticals$13.9B14.7×20.1×n/m3.0×+13%20.4%
Peer median$232.4B40.9×20.6×19.0×5.9×+7%8.3%

More on Bristol-Myers Squibb

Each number over time

Where it ranks

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .